BAO PHARMA-B Surges Over 6% in Session as World's First Synthetic Biology Recombinant Ulinastatin BJ044 Gains Clinical Trial Approval

Deep News07-09

Shares of BAO PHARMA-B (02659) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million.

In late June, the company announced that the clinical trial application for its self-developed BJ044 injection (recombinant ulinastatin) was officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant ulinastatin product developed using synthetic biology technology. With comprehensive advantages in purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products.

Pipeline Synergy and Strategic Differentiation

It is noteworthy that this product forms pipeline synergy with the company's other recombinant protease, KJ101. Together, they validate the company's technological platform capability for "recombinant replacement of traditional biochemical extraction." Leveraging multiple expression systems such as CHO and yeast, the company possesses the replicable capability to continuously transform traditional extraction-based drugs. This approach builds a differentiated recombinant protein innovation pipeline, setting it apart from the homogenized research and development routes in the industry that are crowded with monoclonal antibodies and ADCs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156096333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156096333","market":"us","top_or_hot":-1,"title":"BAO PHARMA-B Surges Over 6% in Session as World's First Synthetic Biology Recombinant Ulinastatin BJ044 Gains Clinical Trial Approval","media":"Deep News","content":"<p>Shares of <b>BAO PHARMA-B</b> (<b>02659</b>) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million.<br><br>\nIn late June, the company announced that the clinical trial application for its self-developed BJ044 injection (recombinant ulinastatin) was officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant ulinastatin product developed using synthetic biology technology. With comprehensive advantages in purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products.<br><br>\n<b>Pipeline Synergy and Strategic Differentiation</b><br><br>\nIt is noteworthy that this product forms pipeline synergy with the company's other recombinant protease, KJ101. Together, they validate the company's technological platform capability for \"recombinant replacement of traditional biochemical extraction.\" Leveraging multiple expression systems such as CHO and yeast, the company possesses the replicable capability to continuously transform traditional extraction-based drugs. This approach builds a differentiated recombinant protein innovation pipeline, setting it apart from the homogenized research and development routes in the industry that are crowded with monoclonal antibodies and ADCs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Surges Over 6% in Session as World's First Synthetic Biology Recombinant Ulinastatin BJ044 Gains Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Surges Over 6% in Session as World's First Synthetic Biology Recombinant Ulinastatin BJ044 Gains Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-09 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>BAO PHARMA-B</b> (<b>02659</b>) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million.<br><br>\nIn late June, the company announced that the clinical trial application for its self-developed BJ044 injection (recombinant ulinastatin) was officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant ulinastatin product developed using synthetic biology technology. With comprehensive advantages in purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products.<br><br>\n<b>Pipeline Synergy and Strategic Differentiation</b><br><br>\nIt is noteworthy that this product forms pipeline synergy with the company's other recombinant protease, KJ101. Together, they validate the company's technological platform capability for \"recombinant replacement of traditional biochemical extraction.\" Leveraging multiple expression systems such as CHO and yeast, the company possesses the replicable capability to continuously transform traditional extraction-based drugs. This approach builds a differentiated recombinant protein innovation pipeline, setting it apart from the homogenized research and development routes in the industry that are crowded with monoclonal antibodies and ADCs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1156096333","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156096333","pubTimestamp":1783563677,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of BAO PHARMA-B (02659) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million. In late June, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02659":"宝济药业-B","WDNA":"WisdomTree BioRevolution Fund"},"translate_title":"宝药业-B盘中大涨超6%，全球首个合成生物学重组乌司他丁BJ044获临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WDNA":1,"02659":1},"content_text":"Shares of BAO PHARMA-B (02659) surged more than 6% in early trading. At the time of writing, the stock is up 2.76%, trading at HK$20.10 with a turnover of HK$7.1887 million.\nIn late June, the company announced that the clinical trial application for its self-developed BJ044 injection (recombinant ulinastatin) was officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant ulinastatin product developed using synthetic biology technology. With comprehensive advantages in purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products.\nPipeline Synergy and Strategic Differentiation\nIt is noteworthy that this product forms pipeline synergy with the company's other recombinant protease, KJ101. Together, they validate the company's technological platform capability for \"recombinant replacement of traditional biochemical extraction.\" Leveraging multiple expression systems such as CHO and yeast, the company possesses the replicable capability to continuously transform traditional extraction-based drugs. This approach builds a differentiated recombinant protein innovation pipeline, setting it apart from the homogenized research and development routes in the industry that are crowded with monoclonal antibodies and ADCs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156096333","isCrawlerRequest":true}